Ex Parte Kovesdi et al - Page 17




                 Appeal No. 2004-1259                                                                                                             
                 Application No. 09/832,355                                                                                                       
                 3.   Lack of Written Description and Enablement of fusion proteins with specified                                                
                 half-life                                                                                                                        
                         The examiner argues there is no written description of fusion proteins with a half-                                      
                 life of at least twice as long as either the first or second peptide portion or both as in                                       
                 claim 6.   The examiner argues that “the specification, as filed, does not disclose the                                          
                 half lives of various proteins, nor does it provide any data or working example of the                                           
                 half-life of any of the claimed fusion proteins”, and that the art of increasing half-lives of                                   
                 proteins is unpredictable.  Answer, page 11.                                                                                     
                         Appellants respond arguing that (Brief, page 7)                                                                          
                         methods for determining protein half-life having long been known to those                                                
                         of ordinary skill in the art, and include for example, pulse chase                                                       
                         experiments as described in Dandri... and Distelhorst...  Moreover the                                                   
                         specification discloses specific structural features of the claimed fusion                                               
                         protein, the absence or presence of which enhances protein stability.  For                                               
                         example the specification discloses that removal of the Ang-1 coiled-coil                                                
                         domain imparts an increased half-life to a fusion protein comprising Ang-1                                               
                         as the non-VEGF peptide portion (see, e.g. paragraph [0108], lines 10-                                                   
                         14.)  The specification also indicates that the inclusion of cysteine                                                    
                         residues in either or both of the VEGF and non-VEGF peptide portions of                                                  
                         the claimed fusion protein renders the fusion protein more resistant to                                                  
                         extracellular degradation... thereby enhancing protein stability.  Fusion                                                
                         protein half-life can also be extended when the non-VEGF peptide portion                                                 
                         comprises an IgG domain as described in the specification at paragraph                                                   
                         [0108], lines 18-22.                                                                                                     
                         The examiner returns, that “it is well known in the art that adding cysteine                                             
                 residues may adversely effect protein folding and activity, and there is no guidance as                                          
                 to where, in any particularly disclosed protein, such cysteine residues could be added.”                                         
                 Answer, page 21.  We find no evidence of record cited by the examiner to support this                                            

                                                                       17                                                                         





Page:  Previous  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  Next 

Last modified: November 3, 2007